Top in endocrinology: Radiation may increase diabetes risk; study questions HbA1c cutoff
Click Here to Manage Email Alerts
Those who were exposed to low levels of nuclear radiation were more likely to develop diabetes, according to recent findings.
The increased diabetes risk was discovered in nuclear emergency workers in Japan who were exposed to 10 mSv to 49 mSv of radiation. However, more studies are needed to learn about the connection, researchers said.
It was the top story in endocrinology last week.
Another top story was about how the HbA1c cutoff for diagnosing diabetes in women aged younger than 50 years might need to be lower than the cutoff for men.
Read these and more top stories in endocrinology below:
Low-dose nuclear radiation exposure may increase risk for diabetes
Exposure to low levels of nuclear radiation may increase the risk for developing diabetes, according to data presented at the European Association for the Study of Diabetes annual meeting. Read more.
HbA1c cutoff for diagnosing diabetes likely too high for premenopausal women
The HbA1c cutoff for diagnosing women younger than 50 years with diabetes may need to be lower than the cutoff for men, according to study findings. Read more.
Metformin provides glycemic, neonatal benefits for women with gestational diabetes
Metformin may lengthen the time until insulin initiation, lower fasting glucose and improve neonatal outcomes for pregnant women with gestational diabetes, according to data from a randomized trial. Read more.
More exposure to natural daylight may improve metabolic metrics in type 2 diabetes
Spending more time in natural light may help improve metabolism for adults with type 2 diabetes, according to data from a small study presented at the European Association for the Study of Diabetes annual meeting. Read more.
Adults with obesity using tirzepatide maintain ‘remarkable’ weight loss at 88 weeks
Adults with obesity receiving tirzepatide lost more than 25% of their body weight and were able to maintain their weight loss for up to 88 weeks, according to data from the SURMOUNT-4 trial. Read more.